We’re always debating internally which company we should cover next. We have a coverage list of 350+ quality companies that we want to study, we just don’t know specifically in which order.
The potential duration of sustainable growth is a top variable we consider when making such a decision. Beyond the obvious benefits, the duration of growth is important because it gives us the best chance to compound our knowledge.
We want to build company-specific knowledge today that we can build on for decades. We also want to get to know founders and management teams that will still be playing their game in years to come. By spending time on companies with long durable growth opportunities, we give ourselves the best chance to compound company-specific knowledge. Years of watching how companies and managers behave can also help build conviction in future challenging times.
A quote from a recent interview with Gavin Baker of Atreides Management reminded us of this point:
“Everybody looks up to Warren Buffett, but almost no one does what he says he does. Warren Buffett has said he doesn't do due diligence. This was a statement about Precision Castparts which is one of his largest acquisitions ever. And everybody just ignored that comment, but it was a profound comment. And what he meant by it was that he didn't need to do due diligence. He had been reading every 10-K published by Precision Castparts for decades. He didn't sit down and do some 60-day deep dive. He didn't need to because he had been doing due diligence on Precision Castparts for decades”
In this regard, Fever Tree (FEVR) is similar to Precision Castparts; a company that we believe has the potential to grow for decades.
We recently held an In Practise Investor Dialogue with two Fever Tree shareholders to explore the investment thesis and the company’s growth opportunities.
When looking at the potential duration of FEVR’s growth, one investor asks the following question:
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities.
© 2023 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research